News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mobius Theraputics™ Commences First Shipments of New Glaucoma Drug



7/9/2012 9:00:49 AM

ST. LOUIS, MO--(Marketwire - July 09, 2012) -

Mobius Therapeutics™, LLC, a St. Louis-based ophthalmic company, has commenced the first commercial shipments of Mitosol® (mitomycin for solution) Kit for Ophthalmic Use. Mitosol® is the first and only formulation of mitomycin-c, specifically approved for an ophthalmic indication.

"The FDA approval of Mitosol® for use in glaucoma surgery was the culmination of six years of collaborative work with the FDA and clinicians," said Ed Timm, President of Mobius Therapeutics. "Only then could we begin the important process of manufacturing sterile filled vials and sterile procedure kits. Now that we have sufficient inventory on hand and manufacturing optimized, we can begin providing surgeons, hospitals, and patients an uninterrupted source of supply of this important agent used in the surgical treatment of glaucoma."

Glaucoma is the second-leading cause of blindness in the United States. It is treated progressively, beginning with pharmaceuticals, then office intervention and finally surgery. Mitosol® provides a new system for delivering a precise dose of its active ingredient, mitomycin-c, for use by ophthalmic surgeons in procedures without any change to their current technique.

"With Mitosol®, all key incentives and stake holders are aligned," continued Timm. "Critical issues concerning safety, sterility, consistency, potency, and economics are now all harmonized in favor of providers and patients. With Mitosol®, everyone wins."

Full prescribing information for Mitosol can be found at www.MobiusTherapeutics.com.

About Mobius Therapeutics, LLC:
Mobius Therapeutics is a commercial stage venture focused on ophthalmic surgery solutions. Its first product, Mitosol®, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery. The glaucoma indication is in active commercialization; the refractive and corneal indications are awaiting approval by the Food and Drug Administration. Mobius is housed within the Center for Emerging Technologies in St. Louis, MO.


CONTACT:
Jim Anderson
Mobius Therapeutics, LLC
314-615-6930
Email Contact

Andy Likes
The Vandiver Group, Inc.
314-991-4641
Email Contact


Read at BioSpace.com


comments powered by Disqus
   
Glaucoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES